PMID-sentid Pub_year Sent_text compound_name comp_offset prot_official_name organism prot_offset 29364548-2 2018 The aim of this study was to evaluate the efficacy of micafungin for the treatment of invasive candidiasis/candidaemia in patients with neutropenia (<500 neutrophils/muL) and without neutropenia. Micafungin 54-64 tripartite motif containing 37 Homo sapiens 169-172 34230874-8 2021 In contrast, the antifungal drug micafungin bearing an unfused tricyclic side chain, emerges as a better ligand of 3CLpro of PEDV compared to Mpro of SARS-CoV-2, based on our calculations. Micafungin 33-43 NEWENTRY Severe acute respiratory syndrome-related coronavirus 142-146 32050883-15 2020 When all the patients (n= 125) were evaluated, a significant decrease in C-reactive protein, an increase in sodium, and a decrease in alanine aminotransferase were observed on the fourth day of micafungin treatment (p<0.05). Micafungin 194-204 C-reactive protein Homo sapiens 73-91 32050883-15 2020 When all the patients (n= 125) were evaluated, a significant decrease in C-reactive protein, an increase in sodium, and a decrease in alanine aminotransferase were observed on the fourth day of micafungin treatment (p<0.05). Micafungin 194-204 glutamic--pyruvic transaminase Homo sapiens 134-158 32050883-19 2020 The patients for which micafungin treatment was chosen due to elevated liver function tests (n= 47, 38%), whether the antifungalinduced or not; alanine aminotransferase and aspartate aminotransferase levels were decreased after micafungin treatment (p= 0.0001 and p= 0.0001, respectively). Micafungin 23-33 glutamic--pyruvic transaminase Homo sapiens 144-168 30300716-4 2018 Micafungin has broad-spectrum fungicidal activity against Candida spp. Micafungin 0-10 histocompatibility minor 13 Homo sapiens 66-69 28791666-6 2018 Micafungin is metabolized by arylsulfatase, catechol-O-methyltransferase, and several cytochrome P450 (CYP) isoenzymes (3A4, 1A2, 2B6 and 2C), but no dose adjustments are necessary in patients with (severe) hepatic dysfunction. Micafungin 0-10 catechol-O-methyltransferase Homo sapiens 44-72 34791369-3 2022 In this study, we characterized the binding of two echinocandins, caspofungin and micafungin, to plasma proteins, human serum albumin (HSA) and human alpha 1-acid glycoprotein (AAG). Micafungin 82-92 albumin Homo sapiens 120-133 34036784-7 2021 This assay demonstrated high reliability and ability for high-throughput screening, identifying a new helicase inhibitor candidate, micafungin (MCFG), from an FDA-approved drug library. Micafungin 132-142 helicase for meiosis 1 Homo sapiens 102-110 34036784-7 2021 This assay demonstrated high reliability and ability for high-throughput screening, identifying a new helicase inhibitor candidate, micafungin (MCFG), from an FDA-approved drug library. Micafungin 144-148 helicase for meiosis 1 Homo sapiens 102-110 33404989-5 2021 RESULTS: Alanine aminotransferase and sequential organ failure assessment score were found to significantly influence the clearance and peripheral distribution volume of micafungin, respectively. Micafungin 170-180 glutamic--pyruvic transaminase Homo sapiens 9-33 32820679-8 2021 MRP4-mediated transport of MPAG was inhibited (from -43% to -84%) by ibuprofen, cefazolin, cefotaxime and micafungin. Micafungin 106-116 ATP binding cassette subfamily C member 4 Homo sapiens 0-4 32047965-0 2020 Assessment of micafungin loading dosage regimens against Candida spp. Micafungin 14-24 histocompatibility minor 13 Homo sapiens 65-68 32047965-15 2020 CONCLUSIONS: The dosage regimen of micafungin which had a loading dose of 1.5 times was more suitable for ICU patients infected by Candida spp. Micafungin 35-45 histocompatibility minor 13 Homo sapiens 139-142 30398618-3 2019 We are reporting a case of a patient with T1DM and severe infection who has reduced insulin needs after starting micafungin therapy. Micafungin 113-123 insulin Homo sapiens 84-91 30398618-8 2019 She was started on micafungin, a potent 1,3-beta-D glucan synthase inhibitor, to broaden antimicrobial coverage when her insulin requirement decreased to zero for >48 hours. Micafungin 19-29 insulin Homo sapiens 121-128 30398618-9 2019 Right after discontinuation of micafungin and her switch to a different antifungal, insulin requirements increased back to her baseline needs. Micafungin 31-41 insulin Homo sapiens 84-91 30398618-10 2019 Results: This is a report of decreased insulin requirements in a patient with T1DM correlating with micafungin administration. Micafungin 100-110 insulin Homo sapiens 39-46 30398618-13 2019 Conclusion: We hypothesize that micafungin may inhibit SGLT-1 function and decrease insulin requirements in patient with T1DM. Micafungin 32-42 solute carrier family 5 member 1 Homo sapiens 55-61 30398618-13 2019 Conclusion: We hypothesize that micafungin may inhibit SGLT-1 function and decrease insulin requirements in patient with T1DM. Micafungin 32-42 insulin Homo sapiens 84-91 29969751-5 2018 Micafungin was well tolerated; 10 patients (6.8%) developed a rise in alanine aminotransferase (ALT) and only 1 patient stopped therapy due to this. Micafungin 0-10 glutamic--pyruvic transaminase Homo sapiens 70-94 29866877-6 2018 MFG caused 2- to 3-fold lower TLR2 and TLR4 mRNA levels than those caused by either organism. Micafungin 0-3 toll like receptor 2 Homo sapiens 30-34 29866877-6 2018 MFG caused 2- to 3-fold lower TLR2 and TLR4 mRNA levels than those caused by either organism. Micafungin 0-3 toll like receptor 4 Homo sapiens 39-43 29084748-3 2018 Micafungin demonstrated good in vitro antifungal activity against Emergomyces (geometric mean minimum effective concentration [GM MEC] 0.1 mug/ml) and Blastomyces (GM MEC <0.017 mug/ml). Micafungin 0-10 C-C motif chemokine ligand 28 Homo sapiens 130-133 29483123-6 2018 In addition, preincubation with micafungin before exposure to human tissue macrophages enhanced the secretion of tumor necrosis factor alpha (TNF-alpha), interleukin-17A (IL-17A), and IL-10 cytokines. Micafungin 32-42 tumor necrosis factor Homo sapiens 113-140 29483123-6 2018 In addition, preincubation with micafungin before exposure to human tissue macrophages enhanced the secretion of tumor necrosis factor alpha (TNF-alpha), interleukin-17A (IL-17A), and IL-10 cytokines. Micafungin 32-42 tumor necrosis factor Homo sapiens 142-151 29483123-6 2018 In addition, preincubation with micafungin before exposure to human tissue macrophages enhanced the secretion of tumor necrosis factor alpha (TNF-alpha), interleukin-17A (IL-17A), and IL-10 cytokines. Micafungin 32-42 interleukin 17A Homo sapiens 154-169 29483123-6 2018 In addition, preincubation with micafungin before exposure to human tissue macrophages enhanced the secretion of tumor necrosis factor alpha (TNF-alpha), interleukin-17A (IL-17A), and IL-10 cytokines. Micafungin 32-42 interleukin 17A Homo sapiens 171-177 29483123-6 2018 In addition, preincubation with micafungin before exposure to human tissue macrophages enhanced the secretion of tumor necrosis factor alpha (TNF-alpha), interleukin-17A (IL-17A), and IL-10 cytokines. Micafungin 32-42 interleukin 10 Homo sapiens 184-189 29084748-3 2018 Micafungin demonstrated good in vitro antifungal activity against Emergomyces (geometric mean minimum effective concentration [GM MEC] 0.1 mug/ml) and Blastomyces (GM MEC <0.017 mug/ml). Micafungin 0-10 C-C motif chemokine ligand 28 Homo sapiens 167-170 28052853-5 2017 The activity of CD101 against Aspergillus fumigatus (n = 56) was similar to that of micafungin and 2-fold greater than that of caspofungin but less than that of anidulafungin. Micafungin 84-94 CD101 molecule Homo sapiens 16-21 28566496-9 2017 A small molecule inhibitor of Pho84, a Food and Drug Administration-approved drug, inhibits TORC1 signaling and potentiates the activity of the antifungals amphotericin B and micafungin. Micafungin 175-185 phosphate transporter PHO84 Saccharomyces cerevisiae S288C 30-35 27394133-8 2016 RESULTS: A 48 hours exposure of human erythrocytes to Micafungin (10 - 25 microg/ml) significantly increased hemolysis and the percentage of annexin-V-binding cells, and significantly decreased forward scatter. Micafungin 54-64 annexin A5 Homo sapiens 141-150 27001813-7 2016 Micafungin uniquely inhibited all transporters, with strong inhibition of MRP4 (4 muM). Micafungin 0-10 ATP binding cassette subfamily C member 4 Homo sapiens 74-78 27001813-7 2016 Micafungin uniquely inhibited all transporters, with strong inhibition of MRP4 (4 muM). Micafungin 0-10 latexin Homo sapiens 82-85 27394133-10 2016 The effect of Micafungin on annexin-V-binding was not significantly modified by removal of extracellular Ca2+, by PKC inhibitor staurosporine (1 microM), p38 kinase inhibitor SB203580 (2 microM), casein kinase 1alpha inhibitor D4476 (10 microM) or pancaspase inhibitor zVAD (10 microM). Micafungin 14-24 annexin A5 Homo sapiens 28-37 26602452-2 2015 This study aimed to investigate the cumulative fraction of response of various echinocandin (caspofungin, micafungin and anidulafungin) dosing regimens against Candida spp. Micafungin 106-116 histocompatibility minor 13 Homo sapiens 168-171 27070500-1 2016 AIM: To describe a predictive model to obtain the area under the plasma concentration versus time curve (AUC) for micafungin to aid in dosing strategies in pediatric patients. Micafungin 114-124 activation induced cytidine deaminase Homo sapiens 128-131 24480373-2 2014 Micafungin is an echinocandin antifungal drug with activity against all major Candida spp. Micafungin 0-10 histocompatibility minor 13 Homo sapiens 86-89 26617583-6 2015 Chemical inhibition of Hsp90 resulted in increased susceptibility of the fungus to itraconazole and micafungin, and decreased its growth in human nails in vitro. Micafungin 100-110 heat shock protein 90 alpha family class A member 1 Homo sapiens 23-28 24480373-4 2014 Micafungin demonstrates in vitro and in vivo activity against Aspergillus spp. Micafungin 0-10 histocompatibility minor 13 Homo sapiens 74-77 24265229-5 2014 RESULTS: Micafungin was able to regulate PMN cytokine response to Aspergillus fumigatus conidia by decreasing the expression of tumour necrosis factor-alpha and increasing that of interleukin-10 (IL-10). Micafungin 9-19 interleukin 10 Mus musculus 196-201 24265229-7 2014 The anti-inflammatory activity of micafungin required IL-10 and occurred through signalling via the TLR2/dectin-1 and TLR3/TRIF pathways. Micafungin 34-44 interleukin 10 Mus musculus 54-59 24265229-7 2014 The anti-inflammatory activity of micafungin required IL-10 and occurred through signalling via the TLR2/dectin-1 and TLR3/TRIF pathways. Micafungin 34-44 toll-like receptor 2 Mus musculus 100-104 24265229-7 2014 The anti-inflammatory activity of micafungin required IL-10 and occurred through signalling via the TLR2/dectin-1 and TLR3/TRIF pathways. Micafungin 34-44 C-type lectin domain family 7, member a Mus musculus 105-113 24265229-7 2014 The anti-inflammatory activity of micafungin required IL-10 and occurred through signalling via the TLR2/dectin-1 and TLR3/TRIF pathways. Micafungin 34-44 toll-like receptor 3 Mus musculus 118-122 24265229-7 2014 The anti-inflammatory activity of micafungin required IL-10 and occurred through signalling via the TLR2/dectin-1 and TLR3/TRIF pathways. Micafungin 34-44 toll-like receptor adaptor molecule 2 Mus musculus 123-127 23786573-3 2014 The aim of this analysis was to evaluate the efficacy of micafungin, caspofungin and liposomal amphotericin B in patients with invasive candidiasis and candidaemia caused by different Candida spp. Micafungin 57-67 histocompatibility minor 13 Homo sapiens 192-195 23786573-10 2014 Micafungin, caspofungin and liposomal amphotericin B exhibit favourable treatment response rates that are comparable for patients infected with different Candida spp. Micafungin 0-10 histocompatibility minor 13 Homo sapiens 162-165 21141064-6 2010 Following the administration of micafungin and itraconazole, the cavity lesion diminished in size, and his eosinophil and serum IgE levels decreased. Micafungin 32-42 immunoglobulin heavy constant epsilon Homo sapiens 128-131 20335786-7 2011 Whether micafungin induces autoantibodies against ADAMTS13 or not, this needs further evaluation, but TTP should be recognized as a possible complication of micafungin. Micafungin 8-18 ADAM metallopeptidase with thrombospondin type 1 motif 13 Homo sapiens 50-58 20835743-0 2011 Endotoxin does not alter the pharmacokinetics of micafungin, but it impairs biliary excretion of micafungin via multidrug resistance-associated protein 2 (ABCC2/Mrp2) in rats. Micafungin 97-107 ATP binding cassette subfamily C member 2 Rattus norvegicus 112-153 20835743-0 2011 Endotoxin does not alter the pharmacokinetics of micafungin, but it impairs biliary excretion of micafungin via multidrug resistance-associated protein 2 (ABCC2/Mrp2) in rats. Micafungin 97-107 ATP binding cassette subfamily C member 2 Rattus norvegicus 155-160 20835743-0 2011 Endotoxin does not alter the pharmacokinetics of micafungin, but it impairs biliary excretion of micafungin via multidrug resistance-associated protein 2 (ABCC2/Mrp2) in rats. Micafungin 97-107 ATP binding cassette subfamily C member 2 Rattus norvegicus 161-165 20835743-6 2011 By protein immunoblot analysis, a significant decrease in the expression of hepatic multidrug resistance-associated protein 2 (ABCC2/Mrp2), which is an efflux protein for micafungin, was observed in endotoxin-treated rats. Micafungin 171-181 ATP binding cassette subfamily C member 2 Rattus norvegicus 84-125 20835743-6 2011 By protein immunoblot analysis, a significant decrease in the expression of hepatic multidrug resistance-associated protein 2 (ABCC2/Mrp2), which is an efflux protein for micafungin, was observed in endotoxin-treated rats. Micafungin 171-181 ATP binding cassette subfamily C member 2 Rattus norvegicus 127-132 20835743-6 2011 By protein immunoblot analysis, a significant decrease in the expression of hepatic multidrug resistance-associated protein 2 (ABCC2/Mrp2), which is an efflux protein for micafungin, was observed in endotoxin-treated rats. Micafungin 171-181 ATP binding cassette subfamily C member 2 Rattus norvegicus 133-137 20835743-7 2011 These results suggest that endotoxin-induced decrease in the hepatobiliary excretion of micafungin is caused, at least in part, by the reduction of Mrp2-mediated hepatobiliary transport ability. Micafungin 88-98 ATP binding cassette subfamily C member 2 Rattus norvegicus 148-152 21420573-3 2011 Although micafungin is active against Aspergillus spp., it has been used mainly in combination therapy for invasive aspergillosis. Micafungin 9-19 histocompatibility minor 13 Homo sapiens 50-53 21905789-4 2011 Micafungin is a member of the echinocandins, a novel class of antifungal agents that target the biosynthesis of beta-1,3-D-glucan, a key fungal cell wall component. Micafungin 0-10 UDP-GlcNAc:betaGal beta-1,3-N-acetylglucosaminyltransferase 2 Homo sapiens 112-120 20832577-3 2010 Both tacrolimus and micafungin are substrates of cytochrome P450 3A4 in vitro. Micafungin 20-30 cytochrome P450 family 3 subfamily A member 4 Homo sapiens 49-68 20606004-4 2010 Micafungin uptake into hepatocytes was inhibited by taurocholate (K(i) = 61 muM), Na(+) depletion (45-55% reduced), and 10 muM rifampin (20-25% reduced); these observations support the involvement of Na(+)-taurocholate-cotransporting polypeptide (NTCP/Ntcp) and, to a lesser extent, organic anion-transporting polypeptides in the hepatic uptake of micafungin. Micafungin 0-10 latexin Homo sapiens 76-79 20606004-4 2010 Micafungin uptake into hepatocytes was inhibited by taurocholate (K(i) = 61 muM), Na(+) depletion (45-55% reduced), and 10 muM rifampin (20-25% reduced); these observations support the involvement of Na(+)-taurocholate-cotransporting polypeptide (NTCP/Ntcp) and, to a lesser extent, organic anion-transporting polypeptides in the hepatic uptake of micafungin. Micafungin 0-10 latexin Homo sapiens 123-126 20606004-4 2010 Micafungin uptake into hepatocytes was inhibited by taurocholate (K(i) = 61 muM), Na(+) depletion (45-55% reduced), and 10 muM rifampin (20-25% reduced); these observations support the involvement of Na(+)-taurocholate-cotransporting polypeptide (NTCP/Ntcp) and, to a lesser extent, organic anion-transporting polypeptides in the hepatic uptake of micafungin. Micafungin 0-10 solute carrier family 10 member 1 Homo sapiens 200-245 20606004-4 2010 Micafungin uptake into hepatocytes was inhibited by taurocholate (K(i) = 61 muM), Na(+) depletion (45-55% reduced), and 10 muM rifampin (20-25% reduced); these observations support the involvement of Na(+)-taurocholate-cotransporting polypeptide (NTCP/Ntcp) and, to a lesser extent, organic anion-transporting polypeptides in the hepatic uptake of micafungin. Micafungin 0-10 solute carrier family 10 member 1 Homo sapiens 247-251 20606004-4 2010 Micafungin uptake into hepatocytes was inhibited by taurocholate (K(i) = 61 muM), Na(+) depletion (45-55% reduced), and 10 muM rifampin (20-25% reduced); these observations support the involvement of Na(+)-taurocholate-cotransporting polypeptide (NTCP/Ntcp) and, to a lesser extent, organic anion-transporting polypeptides in the hepatic uptake of micafungin. Micafungin 0-10 solute carrier family 10 member 1 Homo sapiens 252-256 20606004-6 2010 In vitro biliary excretion of micafungin was reduced by 80 and 75% in the presence of the bile salt export pump (BSEP) inhibitors taurocholate (100 muM) and nefazodone (25 muM), respectively. Micafungin 30-40 ATP binding cassette subfamily B member 11 Homo sapiens 90-111 20606004-6 2010 In vitro biliary excretion of micafungin was reduced by 80 and 75% in the presence of the bile salt export pump (BSEP) inhibitors taurocholate (100 muM) and nefazodone (25 muM), respectively. Micafungin 30-40 ATP binding cassette subfamily B member 11 Homo sapiens 113-117 20606004-6 2010 In vitro biliary excretion of micafungin was reduced by 80 and 75% in the presence of the bile salt export pump (BSEP) inhibitors taurocholate (100 muM) and nefazodone (25 muM), respectively. Micafungin 30-40 latexin Homo sapiens 148-151 20606004-6 2010 In vitro biliary excretion of micafungin was reduced by 80 and 75% in the presence of the bile salt export pump (BSEP) inhibitors taurocholate (100 muM) and nefazodone (25 muM), respectively. Micafungin 30-40 latexin Homo sapiens 172-175 20606004-7 2010 Biliary excretion of micafungin also was reduced in the presence of breast cancer resistance protein inhibitors [N-(4-[2-(1,2,3,4-tetrahydro-6,7-dimethoxy-2-isoquinolinyl)ethyl]-phenyl)-9,10-dihydro-5-methoxy-9-oxo-4-acridine carboxamide (GF120918) (10 muM) and fumitremorgin C (10 muM)]. Micafungin 21-31 latexin Homo sapiens 253-256 20606004-7 2010 Biliary excretion of micafungin also was reduced in the presence of breast cancer resistance protein inhibitors [N-(4-[2-(1,2,3,4-tetrahydro-6,7-dimethoxy-2-isoquinolinyl)ethyl]-phenyl)-9,10-dihydro-5-methoxy-9-oxo-4-acridine carboxamide (GF120918) (10 muM) and fumitremorgin C (10 muM)]. Micafungin 21-31 latexin Homo sapiens 282-285 20606004-9 2010 These results suggest that NTCP/Ntcp and BSEP/Bsep are primarily responsible for hepatobiliary disposition of micafungin in human and rat. Micafungin 110-120 solute carrier family 10 member 1 Homo sapiens 27-31 20606004-9 2010 These results suggest that NTCP/Ntcp and BSEP/Bsep are primarily responsible for hepatobiliary disposition of micafungin in human and rat. Micafungin 110-120 solute carrier family 10 member 1 Homo sapiens 32-36 20606004-9 2010 These results suggest that NTCP/Ntcp and BSEP/Bsep are primarily responsible for hepatobiliary disposition of micafungin in human and rat. Micafungin 110-120 ATP binding cassette subfamily B member 11 Homo sapiens 41-45 20606004-9 2010 These results suggest that NTCP/Ntcp and BSEP/Bsep are primarily responsible for hepatobiliary disposition of micafungin in human and rat. Micafungin 110-120 ATP binding cassette subfamily B member 11 Homo sapiens 46-50 19776753-11 2009 Mean aspartate aminotransferase (AST) showed a statistically significant increase following micafungin treatment, although clinical significance remains unclear. Micafungin 92-102 solute carrier family 17 member 5 Homo sapiens 5-31 19776753-11 2009 Mean aspartate aminotransferase (AST) showed a statistically significant increase following micafungin treatment, although clinical significance remains unclear. Micafungin 92-102 solute carrier family 17 member 5 Homo sapiens 33-36 18638490-0 2008 Involvement of multidrug resistance-associated protein 2 (ABCC2/Mrp2) in biliary excretion of micafungin in rats. Micafungin 94-104 ATP binding cassette subfamily C member 2 Rattus norvegicus 15-56 19727206-1 2009 A 23-year old woman with acute biphenotypic leukemia (ABL) complained of chest pain with cough, high fever and hemoptysis during induction chemotherapy, although she had been treated with anti-biotics and micafungin. Micafungin 205-215 ABL proto-oncogene 1, non-receptor tyrosine kinase Homo sapiens 54-57 19566111-5 2009 Micafungin has very good antifungal activity against a wide range of Candida spp. Micafungin 0-10 histocompatibility minor 13 Homo sapiens 77-80 18638490-0 2008 Involvement of multidrug resistance-associated protein 2 (ABCC2/Mrp2) in biliary excretion of micafungin in rats. Micafungin 94-104 ATP binding cassette subfamily C member 2 Rattus norvegicus 58-63 18638490-0 2008 Involvement of multidrug resistance-associated protein 2 (ABCC2/Mrp2) in biliary excretion of micafungin in rats. Micafungin 94-104 ATP binding cassette subfamily C member 2 Rattus norvegicus 64-68 18638490-2 2008 In the present study, we investigated whether Mrp2 is involved in the transport of micafungin, a newly developed antifungal agent. Micafungin 83-93 ATP binding cassette subfamily C member 2 Rattus norvegicus 46-50 18638490-5 2008 A significant decrease in the biliary clearance of micafungin (~60%) was observed in Eisai hyperbilirubinemic rats, which have a hereditary deficiency in Mrp2. Micafungin 51-61 ATP binding cassette subfamily C member 2 Rattus norvegicus 154-158 18638490-6 2008 The present findings at least suggest that Mrp2 is involved mainly in the hepatobiliary excretion of micafungin in rats. Micafungin 101-111 ATP binding cassette subfamily C member 2 Rattus norvegicus 43-47 18436555-10 2008 By agar dilution analysis, multiple CDR2-overexpressing strains exhibited reduced growth in the presence of micafungin relative to the laboratory strain SC5314. Micafungin 108-118 multidrug resistance ABC transporter similar to S. cerevisiae PDR5 (YOR153W) Candida albicans SC5314 36-40 18436555-12 2008 However, within sets of matched isolates, strains overexpressing CDR2 had a slight increase in micafungin MIC. Micafungin 95-105 multidrug resistance ABC transporter similar to S. cerevisiae PDR5 (YOR153W) Candida albicans SC5314 65-69 18436555-13 2008 Changes in micafungin susceptibility are associated with CDR2 overexpression in agar dilution tests. Micafungin 11-21 multidrug resistance ABC transporter similar to S. cerevisiae PDR5 (YOR153W) Candida albicans SC5314 57-61 16141569-1 2005 The effects of five antifungal drugs, fluconazole, itraconazole, micafungin, miconazole, and voriconazole, on cytochrome P450 (CYP) 1A2-mediated 7-ethoxyresorufin O-deethylation, CYP2D6-mediated debrisoquine 4-hydroxylation, and CYP2E1-mediated chlorzoxazone 6-hydroxylation activities in human liver microsomes were compared. Micafungin 65-75 cytochrome P450 family 1 subfamily A member 2 Homo sapiens 110-135 16205037-3 2005 Fluconazole, micafungin, and voriconazole have lower inhibitory effects on CYP3A4 activities than itraconazole and miconazole, and IC(50) and/or K(i) values against CYP2C9 and CYP2C19 activities are the lowest for miconazole, followed by voriconazole and fluconazole. Micafungin 13-23 cytochrome P450 family 3 subfamily A member 4 Homo sapiens 75-81 16205037-3 2005 Fluconazole, micafungin, and voriconazole have lower inhibitory effects on CYP3A4 activities than itraconazole and miconazole, and IC(50) and/or K(i) values against CYP2C9 and CYP2C19 activities are the lowest for miconazole, followed by voriconazole and fluconazole. Micafungin 13-23 cytochrome P450 family 2 subfamily C member 9 Homo sapiens 165-171 16205037-3 2005 Fluconazole, micafungin, and voriconazole have lower inhibitory effects on CYP3A4 activities than itraconazole and miconazole, and IC(50) and/or K(i) values against CYP2C9 and CYP2C19 activities are the lowest for miconazole, followed by voriconazole and fluconazole. Micafungin 13-23 cytochrome P450 family 2 subfamily C member 19 Homo sapiens 176-183 21694882-2 2008 Through inhibition of beta-1,3-glucan production, an essential component of the fungal cell wall, micafungin exhibits potent antifungal activity against key pathogenic fungi, including Candida and Aspergillus species, while contributing minimal toxicity to mammalian cells. Micafungin 98-108 UDP-GlcNAc:betaGal beta-1,3-N-acetylglucosaminyltransferase 2 Homo sapiens 22-30 17516879-2 2007 By inhibiting the production of beta-1,3-glucan, an essential fungal cell wall component, micafungin has reduced toxicity to mammalian cells while maintaining potent antifungal activity against many pathogenic fungi including polyene- and azole-resistant isolates. Micafungin 90-100 UDP-GlcNAc:betaGal beta-1,3-N-acetylglucosaminyltransferase 2 Homo sapiens 32-40 18360617-9 2007 Finally, caspofungin- or micafungin-containing combination therapy should be a consideration for the treatment of severe infections due to Aspergillus spp. Micafungin 25-35 histocompatibility minor 13 Homo sapiens 151-154 17175357-0 2006 Effects of hepatic CYP3A4 activity on disposition of micafungin in liver transplant recipients with markedly small-for-size grafts. Micafungin 53-63 cytochrome P450 family 3 subfamily A member 4 Homo sapiens 19-25 16172179-1 2005 Micafungin is an antifungal agent metabolized by arylsulfatase with secondary metabolism by catechol-O-methyltransferase. Micafungin 0-10 catechol-O-methyltransferase Homo sapiens 92-120 16205037-5 2005 On the other hand, no inhibition of CYP activities except for CYP3A4 activity by micafungin is observed in vitro, and the blood concentrations of cyclosporine and tacrolimus are not affected by coadministration of micafungin in vivo, suggesting that micafungin would not cause clinically significant interactions with drugs that are metabolized by CYPs via the inhibition of metabolism. Micafungin 81-91 cytochrome P450 family 3 subfamily A member 4 Homo sapiens 62-68 12882619-6 2003 In this review, the pharmacology, spectrum and clinical efficacy of the three leading beta(1,3)glucan synthase inhibitors (caspofungin, micafungin and anidulafungin), which have completed phase III clinical trials, will be discussed and a perspective for the role of these agents in the management of life-threatening mycoses will be offered. Micafungin 136-146 UDP-GlcNAc:betaGal beta-1,3-N-acetylglucosaminyltransferase 2 Homo sapiens 86-94 15969931-0 2005 Effect of micafungin on cytochrome P450 3A4 and multidrug resistance protein 1 activities, and its comparison with azole antifungal drugs. Micafungin 10-20 cytochrome P450 family 3 subfamily A member 4 Homo sapiens 24-43 15969931-0 2005 Effect of micafungin on cytochrome P450 3A4 and multidrug resistance protein 1 activities, and its comparison with azole antifungal drugs. Micafungin 10-20 ATP binding cassette subfamily B member 1 Homo sapiens 48-78 15969931-1 2005 The effects of micafungin on cytochrome P450 3A4 (CYP3A4) metabolic and multidrug resistance protein 1 (MDR1) transport activities were investigated and compared with those of amphotericin B and four azole antifungal drugs (ketoconazole, itraconazole, fluconazole and miconazole). Micafungin 15-25 cytochrome P450 family 3 subfamily A member 4 Homo sapiens 29-48 15969931-1 2005 The effects of micafungin on cytochrome P450 3A4 (CYP3A4) metabolic and multidrug resistance protein 1 (MDR1) transport activities were investigated and compared with those of amphotericin B and four azole antifungal drugs (ketoconazole, itraconazole, fluconazole and miconazole). Micafungin 15-25 cytochrome P450 family 3 subfamily A member 4 Homo sapiens 50-56 16100295-2 2005 Micafungin is an echinocandin antifungal agent and a mild inhibitor of CYP3A metabolism in vitro. Micafungin 0-10 cytochrome P450 family 3 subfamily A member 4 Homo sapiens 71-76 16027407-2 2005 Micafungin is an antifungal agent and a mild inhibitor of CYP3A-mediated metabolism in vitro. Micafungin 0-10 cytochrome P450 family 3 subfamily A member 4 Homo sapiens 58-63 15744091-3 2005 Alteration in the serum unbound fraction of micafungin after CCl4 treatment was unlikely in light of the serum albumin, bilirubin, creatinine, and urea nitrogen. Micafungin 44-54 C-C motif chemokine ligand 4 Rattus norvegicus 61-65 10817741-2 2000 The MIC of FK463 was lower than those of azoles and amphotericin B against CDR1-expressing C26 and CaMDR-expressing C40 strains. Micafungin 11-16 cerebellar degeneration related antigen 1 Mus musculus 75-79